Results 151 to 160 of about 86,846 (266)
Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review. [PDF]
Li D, Lu J, Li Q, Deng H, Tan S.
europepmc +1 more source
Here we developed Am@SExo, a dual‐functional engineered exosome that coordinates CD47–SIRPα checkpoint blockade with Arg1 mRNA–mediated metabolic reprogramming. Surface SIRPα promotes recognition of apoptotic cells and plaque targeting, while Arg1 expression enhances arginine–ornithine metabolism, Rac1 activation, and actin remodeling in macrophages ...
Danwen Zheng +17 more
wiley +1 more source
Endothelial cells as targets of immune checkpoint blockade. [PDF]
Korman AJ, Taylor M, Stephen Hodi F.
europepmc +1 more source
This study unveils an unrecognized pro‐inflammatory epitranscriptomic checkpoint in psoriasis. By installing m7G modifications on the 5′ UTR of Bdkrb1 mRNA, METTL1 enhances receptor stability to orchestrate keratinocyte‐driven neutrophil recruitment via p38 MAPK signaling.
Chang Zhang +10 more
wiley +1 more source
Eutectic mixtures from trans‐vaccenic acid (TVA) and stearic acid, which served as phase‐change material to encapsulate IR780, forming NIR‐responsive nanoparticles. IR780@TVA LNPs induce photothermal therapy and initiate adaptive anti‐tumor immunity.
Kang Liu +12 more
wiley +1 more source
Antibody-lectin chimeras for glyco-immune checkpoint blockade. [PDF]
Stark JC +20 more
europepmc +1 more source
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai +12 more
wiley +1 more source
Immunoglobulin GM (γ marker) allotypes expressed on IgG1 as potential genetic markers of response to immune checkpoint blockade therapy. [PDF]
Pandey JP.
europepmc +1 more source
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo +14 more
wiley +1 more source
Immune Checkpoint Blockade in Hematological Malignancies: Current Status and Future Directions. [PDF]
Lau HC, Kwong YL.
europepmc +1 more source

